Belén Garijo on Q2 results from Merck

Belén Garijo shared a post on LinkedIn:

“We published our Q2 results today! Earlier this year, we committed to returning to growth in 2024, and already in Q2, we delivered organic sales growth, with EBITDA pre remaining around stable.

Our strong performance in Q2, driven by Healthcare and Electronics, coupled with the progressive recovery of Life Science, reinforces our confidence in achieving profitable growth for the rest of 2024. This is the result of the combined efforts of our 63,000 colleagues across the globe. Thank you all!”

Proceed to the video.
Source: Belén Garijo/LinkedIn

Belén Garijo is the Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. She joined the company in 2011 as Chief Operating Officer of the Biopharma business, becoming President and CEO of Healthcare in 2015.

In July 2020, Belén Garijo was appointed Vice Chairman of the Executive Board and Deputy CEO in addition to her role as CEO of the Healthcare business. She moved from Deputy CEO to CEO in May 2021.

Under her leadership, Healthcare at Merck KGaA, Darmstadt, Germany, has become a key player in the area of oncology, immunology and immuno-oncology, after the profound repositioning of the portfolio, the reorganization of R&D and the transformation of the commercial model.

Before joining Merck, Belén Garijo served as the Senior Vice President of Global Operations Europe at Sanofi-Aventis and Global Integration Leader of Genzyme after its acquisition by Sanofi. She previously held several local and global executive positions, both in R&D and commercial, at various companies at the forefront of the Healthcare sector.

She started her career as a practicing physician at La Paz hospital in Madrid before moving to the pharmaceutical industry. She is a medical doctor, specialized in clinical pharmacology.